SpyGlass Pharma, Inc. SGP
—
27.07
(0.58)
(2.10%)
as of 25 Sep
- Market cap
- $924.8M
- P/E
- 0.0×
Follow SGP
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Current Ratio |
12.67 | 2.23 | 25.56 |
Net Debt/EBITDA |
2.63 | 0.61 | 2.86 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | — |
Operating CF/Net income |
0.82 | 0.76 | 0.92 |
Capex/Depreciation |
(1.29) | (7.35) | (1.76) |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 50.05% | 62.41% | 0.00% | |
| (57.29%) | (90.48%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(38.89%) | (247.51%) | (33.74%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(15.11) | (13.43) | (7.19) |
Cash per Share |
48.46 | 9.10 | 23.20 |
Shareholders Equity per Share |
(44.58) | (33.82) | (18.98) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(44.58) | (33.82) | (18.98) |
Free Cash Flow |
(33.49) | (24.02) | (12.49) |
Working Capital |
100.18 | 9.62 | 39.03 |
Capital Expenditures |
(0.79) | (1.99) | (0.22) |
Net Current Asset Value |
(105.93) | (66.39) | (33.52) |
| Other line items | |||
Quick Ratio |
12.57 | 2.14 | 25.45 |
Depreciation/Fixed assets |
0.26 | 0.13 | 0.27 |
Cash ROIC |
(407.49%) | 54.73% | (173.59%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(14.75) | (12.32) | (7.06) |
Capex per Share |
(0.36) | (1.11) | (0.12) |
Average Receivables |
0.43 | 0.27 | — |
Average Payables |
2.34 | 1.31 | — |
Average Assets |
69.59 | 32.23 | — |
Average Common Equity |
(79.66) | (46.73) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% |
Columns are period end dates